Search - tctmd.com

Displaying 1 - 20 of 100

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Better LDL Control After STEMI Means Less Neoatherosclerosis

Yael L. Maxwell

December 23, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

Presentation TCT India 2025

Newer Lipid therapy Guidelines – Role of PCSK9 Inhibitors in ACS

Presenter: M. Srinivasa Rao

July 26, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Daily News

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

Todd Neale

June 13, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

Better LDL Control After STEMI Means Less Neoatherosclerosis

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

September 2025 Dispatch for the CV Team

Newer Lipid therapy Guidelines – Role of PCSK9 Inhibitors in ACS

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Top Coronary Artery Disease News of 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

LDL Control Remains Poor in CAD Patients: NHANES

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content